GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (STU:19KA) » Definitions » Total Equity

Cormedix (STU:19KA) Total Equity : €53.37 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cormedix Total Equity?

Cormedix's total equity for the quarter that ended in Mar. 2024 was €53.37 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Cormedix Total Equity Historical Data

The historical data trend for Cormedix's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cormedix Total Equity Chart

Cormedix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.28 36.35 55.58 51.98 64.32

Cormedix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.37 45.27 77.96 64.32 53.37

Cormedix Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Cormedix's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=75.249-10.929
=64.32

Cormedix's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=62.582-9.21
=53.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cormedix Total Equity Related Terms

Thank you for viewing the detailed overview of Cormedix's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cormedix (STU:19KA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (STU:19KA) » Definitions » Total Equity
Comparable Companies
IMRX MACK PSTX ATXS CBUS DNTH GRTS IVVD FATE INZY OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CRMD:USA
Address
300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922
Website
https://www.cormedix.com
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.

Cormedix (STU:19KA) Headlines

No Headlines